Rare, Protein-Altering Variants in AS3MT and Arsenic Metabolism Efficiency: A Multi-Population Association Study
Dayana A. Delgado,Meytal Chernoff,Lei Huang,Lin Tong,Lin Chen,Farzana Jasmine,Justin Shinkle,Shelley A. Cole,Karin Haack,Jack Kent,Jason Umans,Lyle G. Best,Heather Nelson,Donald Vander Griend,Joseph Graziano,Muhammad G. Kibriya,Ana Navas-Acien,Margaret R. Karagas,Habibul Ahsan,Brandon L. Pierce
DOI: https://doi.org/10.1289/ehp8152
IF: 11.035
2021-04-01
Environmental Health Perspectives
Abstract:BACKGROUND: Common genetic variation in the arsenic methyltransferase (<i>AS3MT</i>) gene region is known to be associated with arsenic metabolism efficiency (AME), measured as the percentage of dimethylarsinic acid (DMA%) in the urine. Rare, protein-altering variants in <i>AS3MT</i> could have even larger effects on AME, but their contribution to AME has not been investigated.OBJECTIVES: We estimated the impact of rare, protein-coding variation in <i>AS3MT</i> on AME using a multi-population approach to facilitate the discovery of population-specific and shared causal rare variants.METHODS: We generated targeted DNA sequencing data for the coding regions of <i>AS3MT</i> for three arsenic-exposed cohorts with existing data on arsenic species measured in urine: Health Effects of Arsenic Longitudinal Study (HEALS, <math><mrow><mi>n</mi><mo>=</mo><mn>2,434</mn></mrow></math>), Strong Heart Study (SHS, <math><mrow><mi>n</mi><mo>=</mo><mn>868</mn></mrow></math>), and New Hampshire Skin Cancer Study (NHSCS, <math><mrow><mi>n</mi><mo>=</mo><mn>666</mn></mrow></math>). We assessed the collective effects of rare (allele frequency <math><mrow><mo><</mo><mn>1</mn><mo>%</mo></mrow></math>), protein-altering <i>AS3MT</i> variants on DMA%, using multiple approaches, including a test of the association between rare allele carrier status (yes/no) and DMA% using linear regression (adjusted for common variants in 10q24.32 region, age, sex, and population structure).RESULTS: We identified 23 carriers of rare-protein-altering <i>AS3MT</i> variant across all cohorts (13 in HEALS and 5 in both SHS and NHSCS), including 6 carriers of predicted loss-of-function variants. DMA% was 6-10% lower in carriers compared with noncarriers in HEALS [<math><mrow><mi>β</mi><mo>=</mo><mo>-</mo><mn>9.4</mn></mrow></math> (95% CI: <math><mrow><mo>-</mo><mn>13.9</mn></mrow></math>, <math><mrow><mo>-</mo><mn>4.8</mn></mrow></math>)], SHS [<math><mrow><mi>β</mi><mo>=</mo><mo>-</mo><mn>6.9</mn></mrow></math> (95% CI: <math><mrow><mo>-</mo><mn>13.6</mn></mrow></math>, <math><mrow><mo>-</mo><mn>0.2</mn></mrow></math>)], and NHSCS [<math><mrow><mi>β</mi><mo>=</mo><mo>-</mo><mn>8.7</mn></mrow></math> (95% CI: <math><mrow><mo>-</mo><mn>15.6</mn></mrow></math>, <math><mrow><mo>-</mo><mn>2.2</mn></mrow></math>)]. In meta-analyses across cohorts, DMA% was 8.7% lower in carriers [<math><mrow><mi>β</mi><mo>=</mo><mo>-</mo><mn>8.7</mn></mrow></math> (95% CI: <math><mrow><mo>-</mo><mn>11.9</mn></mrow></math>, <math><mrow><mo>-</mo><mn>5.4</mn></mrow></math>)].DISCUSSION: Rare, protein-altering variants in <i>AS3MT</i> were associated with lower mean DMA%, an indicator of reduced AME. Although a small percentage of the population (0.5-0.7%) carry these variants, they are associated with a 6-10% decrease in DMA% that is consistent across multiple ancestral and environmental backgrounds. https://doi.org/10.1289/EHP8152.
environmental sciences,public, environmental & occupational health,toxicology